Comparative mydriatic study: tropicamide vs. biosimilar in normal and diabetic patients with quality control analysis.
To compare the effectiveness of tropicamide and its biosimilar drug in normal and diabetic patients.
The prospective cohort study was conducted at Amanat Eye Hospital on March 5, 2023 to 5 December, 2023, and comprised individuals aged 40-50 years. Diabetic patients formed group A, while healthy controls were in group B. Tropicamide 1% was used for mydriasis in the left eye of all the subjects, and a biosimilar drug was used for mydriasis in the right eye. After administration, the size of the pupil was analysed. Data was analysed using Paired t-tests for continuous variables and McNemar's test for categorical variables.
Of the 300 subjects (150 males, 150 females), 150(50%) were in each of the two groups. In group B, 29(19.33%) eyes were perfectly dilated in response to tropicamide compared to 23(15.43%) with biosimilar drug. In group A, the corresponding values were 53(35.33%) and 25(16.66%), respectively.
Tropicamide was found to be more effective compared to its biosimilar drug. Besides, tropicamide was more effective in healthy individuals compared to diabetic individuals.
The prospective cohort study was conducted at Amanat Eye Hospital on March 5, 2023 to 5 December, 2023, and comprised individuals aged 40-50 years. Diabetic patients formed group A, while healthy controls were in group B. Tropicamide 1% was used for mydriasis in the left eye of all the subjects, and a biosimilar drug was used for mydriasis in the right eye. After administration, the size of the pupil was analysed. Data was analysed using Paired t-tests for continuous variables and McNemar's test for categorical variables.
Of the 300 subjects (150 males, 150 females), 150(50%) were in each of the two groups. In group B, 29(19.33%) eyes were perfectly dilated in response to tropicamide compared to 23(15.43%) with biosimilar drug. In group A, the corresponding values were 53(35.33%) and 25(16.66%), respectively.
Tropicamide was found to be more effective compared to its biosimilar drug. Besides, tropicamide was more effective in healthy individuals compared to diabetic individuals.